• ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[비즈트리뷴] “큐로셀, 국내 CAR-T치료제 대체하게 될 것” – 유진투자

2024/12/12

“큐로셀, 국내 CAR-T치료제 대체하게 될 것” – 유진투자 – 비즈트리뷴

Prev큐로셀 CAR-T 치료제 ‘안발셀’, 허가-평가-협상 병행 2호 선정
Next[더벨] 예상보다 늦어진 품목허가, 빠른 상업화 위한 전략적 지연
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.